newratings.com  Sep 16  Comment 
THOUSAND OAKS (dpa-AFX) - AcelRx Pharmaceuticals Inc. (ACRX) was up more than 9% on Thursday, following positive results for ARX-04 in the management of moderate-to-severe acute pain in post-operative study patients, including elderly patients and...
Benzinga  Sep 15  Comment 
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) disclosed that its investigational product candidate ARX-04 provided solid tolerance level in an open-label Phase three trial for post operative acute pain treatment. This included elderly patients, as...
newratings.com  Sep 15  Comment 
NEW YORK CITY (dpa-AFX) - Shares of Acasti Pharma (ACST)(APO.V) surged 123% on Wednesday, following positive data from its bioavailability study of CaPre for the treatment of patients with severe hypertriglyceridemia. The bioavailability study...
Benzinga  Aug 15  Comment 
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) disclosed top line results of its ARX-04 final stage study, which met its primary endpoint. The specialty pharmaceutical company indicated 76 adults were given the treatment with ARX-04 in this trial...
FierceBiotech  Aug 15  Comment 
AcelRx posts new data for potent military pain drug, but results cloudy badams Mon, 08/15/2016 - 06:59


AcelRx (NASDAQ:ACRX) is a pharmaceutical company which develops and sells treatments for acute and breakthrough pain. In particular, the product would help with post-operative pain. AcelRx has completed Phase 2 and is preparing to conduct two Phase 3 clinical trials for its lead product.[1]

Acute and breakthrough pain associated with the post-operation period is often treated with intravenous (IV) opioid injections. These tend to have negative side effects due to the usage of morphine. In addition, there can be delivery and programming errors from the complex infusion pumps used to provide the patients with the opioid. AcelRx's lead candidate involves a patient administered dosage sublingual, or below the tongue. AcelRx also uses Sufentanil rather than morphine.[2]

The company's initial public offering of stock on the NASDAQ occurred on February 10, 2011. The company offered 8M shares each for $5. The company originally planned to sell 5.8M shares within the range of $12-$14. This would have made the deal worth $75.4M, but the drop in price brought the total deal to $40M even after the rise in shares sold. The lead underwriter of the deal was Piper Jaffray Companies (PJC). Canaccord Capital (BER:C6U), Cowen Group (COWN), and JMP Group (JMP) acted as comanagers.[3]

Because AcelRx does not have a commercially viable yet, the company is still in the pre-revenue stage. As a result, the company has incurred high Research & Development expenses without making money. For the first 9 months of 2010, AcelRx's net loss was $10.8M, 58% of which was from research and development expenses. [4]


  1. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg1
  2. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Sufentanil NanoTabs" pg1-2
  3. Renaissance Capital - IPO Home "AcelRx prices IPO at $5, below the original $12-$14 range" 11 Feb 2011
  4. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Summary Financial Data" pg10
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki